MONTREAL--(BUSINESS WIRE)-- At the 2011 Annual Meeting of the Canadian Association for Clinical Microbiology and Infectious Diseases (CACMID), the companies i2A Canada and Bruker Ltd. announced together that they have met the relevant Health Products and Food Branch (HPFB) of Health Canada regulations for the Bruker IVD MALDI Biotyper, and that this product is now available for sale as a Class 1 Medical Device to all clinical microbiology sites in Canada.
i2a Canada, as the exclusive sub-distributor of the Bruker IVD MALDI Biotyper for clinical microbiology in Canada since 2009, offers this robust, rapid and cost-effective method for bacterial identification. Optionally, the IVD MALDI Biotyper is also available in combination with the i2A SirWeb-MALDITOF software as a fully integrated solution for clinical microbiology laboratories.
The Bruker MALDI Biotyper is a MALDI-TOF mass spectrometry based bench-top platform for rapidly identifying bacteria and yeasts. Its carefully curated database includes quality-controlled entries of over 3,900 strains from over 2,000 well-characterized microbial species. Starting from a cultured colony, identification is performed by matching the measured protein fingerprint against the proprietary MALDI Biotyper database, followed by a final review by a trained microbiologist. Including the database search, identification can be performed in minutes. Multiple colonies can be spotted on a single target, and about 30-60 identifications can be performed every hour with no pre-testing required. The MALDI Biotyper offers considerably faster time-to-result (TTR), high specificity, very low false positive rates, low operational costs, and low technical barriers for new operators.
The MALDI Biotyper is available in a research-use-only version, as well as in the IVD MALDI Biotyper IVD-CE version according to EU directive EC/98/79 in certain European countries. Bruker has installed over 250 MALDI Biotyper systems worldwide in routine clinical and other laboratories for microbial identifications. Over 50 peer-reviewed papers have examined the capabilities of the MALDI Biotyper with excellent results reported to date. The Bruker MALDI Biotyper is rapidly becoming a new standard for robust, rapid microbial identification. Further applications are under development, including the research-use-only MALDI Sepsityper™ consumables kit for identification from blood cultures using the BD (Becton, Dickinson and Company) Bactec system and associated BD consumables. This rapid method for processing positive blood culture bottles is intended to reduce time to result for this critical specimen with results available in as little as 30 minutes.
Mr. George Goedesky, Bruker’s Executive Director - MALDI Biotyper, stated: “We have been very encouraged by the excellent results seen in clinical evaluations on-going in Canada and the results generated have been very consistent to those seen in papers published to date. The Bruker IVD MALDI Biotyper offers clinical microbiologists an opportunity to reduce turn-around time, time-to-result and improve identification accuracy with an efficient, cost effective modern, molecular method. We are pleased to be partnering with i2A to bring this revolutionary technology to the clinical microbiology market in Canada.”
About i2A Canada
Founded in 1988, i2a SA in France, and i2a Canada (2003) in Val-David, Quebec develop, manufacture and sell instruments, epidemiology and nosocomial infection control management software and reagents serving life science researchers, clinical laboratories and veterinarian laboratories. For more information about i2a, please visit www.i2a.info (no reagents yet available in Canada).
About Bruker Ltd. (Canada)
Bruker Ltd. in Milton, Ontario was incorporated in 1970, and is the Canadian subsidiary of Bruker Corporation (NASDAQ: BRKR). The Bruker MALDI Biotyper produces a proteomic fingerprint which when evaluated by the microbiology technologist in conjunction with other data can provide rapid and robust identifications of various types of micro-organisms. It can be applied to gram-positive and gram-negative bacteria, and yeasts without pretesting such as gram stain, catalase or oxidase. Starting from isolated colonies on culture plates, identifications can be made in less than 10 minutes at low cost. Located in Milton, Ontario are the sales, service and support center for Bruker Ltd. for Canada. For more information about Bruker Corporation, please visit www.bruker.com.
CONTACT:
i2A:
Pierre Lacroix, +1-514-910-8051
Directeur général
[email protected]
or
Bruker:
George Goedesky, +1-978-663-3660
Executive Director-MALDI Biotyper
[email protected]
KEYWORDS: United States North America Canada Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Infectious Diseases Medical Devices Other Health Research Other Science Science General Health
MEDIA:
| Logo |